Skip to main content
SpringerLink
Log in

A combination of four serum miRNAs for screening of lung adenocarcinoma

  • Research Article
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Serum microRNAs (miRNAs), with their noticeable stability and unique expression pattern in patients with various diseases, are robust novel non-invasive biomarkers for cancer detection. The objective of this study was to identify specific serum miRNAs as potential biomarkers for screening lung adenocarcinoma. The study was divided into a screening phase, training phase, and validation phase. The expression of 46 serum miRNAs from lung adenocarcinoma (LUAD) patients and healthy controls (HCs) were examined in the screening phase. The expression of the most dysregulated miRNAs was further verified in training (30 LUAD vs. 30 HCs) and validation (82 LUAD vs. 90 HCs) phases. Seven serum miRNAs (miR-142-5p, miR-203a-5p, miR-409-3p, miR-223-3p, miR-150-5p, miR-486-5p and miR-146a-5p) in LUAD patients were significantly dysregulated compared to those in HCs. Their ability to diagnose lung cancer was also significant, with miR-142-5p (AUC = 0.743), miR-409-3p (AUC = 0.755), miR-223-3p (AUC = 0.828) and miR-146a-5p (AUC = 0.745) being more prominent. The combined use of these four could enhance diagnostic value (AUC = 0.933). Our findings define a distinct miRNA expression profile in the serum of LUAD patients. The four-miRNA panel (miR-142-5p, miR-409-3p, miR-223-3p and 146a-5p) may be considered as a novel, non-invasive biomarker for LUAD early detection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Boloker G, Wang C, Zhang J. Updated statistics of lung and bronchus cancer in United States (2018). J Thorac Dis. 2018;10(3):1158–61. https://doi.org/10.21037/jtd.2018.03.15.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

    Article  PubMed  Google Scholar 

  3. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. https://doi.org/10.1056/NEJMoa1102873.

    Article  Google Scholar 

  4. Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung cancer. 2013;80(1):45–9. https://doi.org/10.1016/j.lungcan.2013.01.002.

    Article  PubMed  Google Scholar 

  5. Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers–blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011;8(3):142–50. https://doi.org/10.1038/nrclinonc.2010.220.

    Article  PubMed  Google Scholar 

  6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.

    Article  CAS  PubMed  Google Scholar 

  7. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66. https://doi.org/10.1038/nrc1997.

    Article  CAS  PubMed  Google Scholar 

  8. Todeschini P, Salviato E, Paracchini L, Ferracin M, Petrillo M, Zanotti L, Tognon G, Gambino A, Calura E, Caratti G, Martini P, Beltrame L, Maragoni L, Gallo D, Odicino FE, Sartori E, Scambia G, Negrini M, Ravaggi A, D'Incalci M, Marchini S, Bignotti E, Romualdi C. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts. Cancer Lett. 2017;388:320–7. https://doi.org/10.1016/j.canlet.2016.12.017.

    Article  CAS  PubMed  Google Scholar 

  9. Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, Li SP, Xiong Y, Yuan Y, Min J, Jia WH, Jie Y, Chen MS, Chen MX, Fang JH, Zeng C, Zhang Y, Guo RP, Wu Y, Lin G, Zheng L, Zhuang SM. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 2015;16(7):804–15. https://doi.org/10.1016/S1470-2045(15)00048-0.

    Article  CAS  PubMed  Google Scholar 

  10. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, Wang Z, Qiu S, Wang X, Yang G, Sun H, Tang Z, Wu Y, Zhu H, Fan J. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29(36):4781–8. https://doi.org/10.1200/JCO.2011.38.2697.

    Article  CAS  PubMed  Google Scholar 

  11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8. https://doi.org/10.1006/meth.2001.1262.

    Article  CAS  PubMed  Google Scholar 

  12. Abdollahi A, Rahmati S, Ghaderi B, Sigari N, Nikkhoo B, Sharifi K, Abdi M. A combined panel of circulating microRNA as a diagnostic tool for detection of the non-small cell lung cancer. QJM Mon J Assoc Phys. 2019;112(10):779–85. https://doi.org/10.1093/qjmed/hcz158.

    Article  CAS  Google Scholar 

  13. Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical evaluation of microRNA expression profiling in non-small cell lung cancer. Lung Cancer. 2013;81(3):388–96. https://doi.org/10.1016/j.lungcan.2013.05.007.

    Article  CAS  PubMed  Google Scholar 

  14. Khandelwal A, Seam RK, Gupta M, Rana MK, Prakash H, Vasquez KM, Jain A. Circulating microRNA-590-5p acts as a liquid biopsy marker in non-small cell lung cancer. Cancer Sci. 2019. https://doi.org/10.1111/cas.14199.

    Article  Google Scholar 

  15. Yang X, Zhang Q, Zhang M, Su W, Wang Z, Li Y, Zhang J, Beer DG, Yang S, Chen G. Serum microRNA signature is capable of early diagnosis for non-small cell lung cancer. Int J Biol Sci. 2019;15(8):1712–22. https://doi.org/10.7150/ijbs.33986.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang Y, Chen Z, Chen F, Wang D. miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2. Oncology letters. 2013;6(2):359–66. https://doi.org/10.3892/ol.2013.1375.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Huang L, Li F, Deng P, Hu C. MicroRNA-223 promotes tumor progression in lung cancer A549 cells via activation of the NF-kappaB signaling pathway. Oncol Res. 2016;24(6):405–13. https://doi.org/10.3727/096504016X14685034103437.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by Science and Technology Development Fund Project of Shenzhen (no. JCYJ20180507183102747) and Clinical Research Project of Shenzhen Health Commission (no. SZLY2018023).

Author information

Authors and Affiliations

  1. Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen, 518036, Guangdong, China

    Jingyao Wang, Chunduo Zhang, Xiqi Peng, Kaihao Liu, Liwen Zhao, Xuan Chen & Yongqing Lai

  2. Shantou University Medical College, Shantou, 515041, Guangdong, China

    Xiqi Peng & Xuan Chen

  3. Anhui Medical University, Hefei, 230032, Anhui, China

    Kaihao Liu & Liwen Zhao

  4. Department of Invasive Technology, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen, 518036, Guangdong, China

    Hongjian Yu

Authors
  1. Jingyao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chunduo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiqi Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kaihao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liwen Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xuan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hongjian Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yongqing Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hongjian Yu or Yongqing Lai.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study complied with the Helsinki Declaration and was approved by the Ethics Committee of Peking University Shenzhen Hospital (BCYJ2017001). Participants signed an informed consent form before sample collection.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, J., Zhang, C., Peng, X. et al. A combination of four serum miRNAs for screening of lung adenocarcinoma. Human Cell 33, 830–838 (2020). https://doi.org/10.1007/s13577-020-00346-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-020-00346-6

Keywords

Search

Navigation